CRISPR/Cas9 is presented as a genome-editing strategy within an integrated framework to enhance maize resilience under climate change. The abstract links it to identifying and acting on precise targets for breeding climate-resilient cultivars.
First-pass extracted concept
CRISPR-Cas9
Candidate: concept label8 source documents16 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
next-generation genome editing
Extracted Explainers
What the tool is doing
CRISPR-Cas9 is presented as a genetic engineering technology that enables modification of T cells for adoptive immunotherapy.
The abstract identifies CRISPR/Cas9 as a cutting-edge technology being explored for sustainable pest management in plants.
CRISPR/Cas9 is described as a genome editing approach relevant to targeted integration strategies.
CRISPR-Cas9 is presented as one of the targeted gene-therapy methods discussed for retinal diseases.
Resources required
The abstract implies a need for maize transformation or delivery capability, including newer in planta or transformation-free protocols. Practical deployment is also constrained by regulatory and cost considerations.
The abstract supports a need for engineering methods and effective cell or tissue delivery capabilities.
What problem it solves
It helps address the need for precise intervention on complex stress-adaptive traits in maize. The review frames it as part of the toolkit for developing climate-resilient cultivars.
It helps create engineered cellular therapies and improve established T-cell products.
It is presented as part of the biotechnology toolkit for engineering anti-herbivore traits.
It is grouped with targeted gene therapies intended to induce normal gene or protein expression in affected cells.
What it does not solve
The abstract does not claim that genome editing alone solves field deployment barriers. It explicitly notes persistent issues with transformation efficiency, regulation, and implementation cost.
The abstract states that engineered traits still face limited field validation, ecological trade-offs, and regulatory hurdles.
The abstract explicitly states that CRISPR/Cas9 can amplify risk through off-target double-strand breaks and chromosomal rearrangements.
The abstract does not specify disease-specific performance or claim that delivery and engineering barriers are resolved.
Alternatives
The review contrasts genome editing with genomic selection, environmental genomic selection, and multi-omics-guided breeding approaches.
The same sentence contrasts CRISPR/Cas9 with RNA interference and metabolic engineering as other technologies in this area.
The abstract mentions emerging alternatives including base editing, prime editing, and hybrid nucleases.
The source contrasts CRISPR-Cas9-based therapy with optogenetics and RNA interference using noncoding RNAs.
Evidence Snippets
We present an integrated framework that encompasses CRISPR/Cas9 and next-generation genome editing
Further, we aim to see the potential of SWCNTs and CDs for a CRISPR-Cas9 gene construct delivery system, with phytoene desaturase (PDS) as the target gene.
We first validated the system using the CRISPR/Cas9 genome editing platform, confirming its effectiveness.
The editorial explicitly highlights a review on CRISPR/Cas9 for climate resilience in staple crops and frames genome editing for climate-change adaptation in agriculture around this platform.
Propelled by viral and non-viral-based technologies, such as CRISPR-Cas9, genetic engineering offers novel opportunities
The review further discusses insect counterstrategies and explores cutting-edge technologies-CRISPR/Cas9, RNA interference, and metabolic engineering that are reshaping pest management.
CRISPR/Cas9-mediated genome editing further amplifies risks via off-target double-strand breaks and chromosomal rearrangements.
targeted gene therapies, such as methods based on CRISPR-Cas9 and RNA interference with noncoding RNAs
Supporting Sources
Linked Claims
The integrated biotechnology approaches discussed have deepened understanding of complex stress-adaptive traits and genotype-by-environment interactions and revealed precise targets for breeding climate-resilient maize cultivars.
Quoted textsource-backed
These approaches have significantly deepened our understanding of complex stress-adaptive traits and genotype-by-environment interactions, revealing precise targets for breeding climate-resilient cultivars.
Infiltration of CRISPR-Cas9 vectors targeting PDS in cowpea leaves resulted in multiplex editing and large deletions within the target gene.
Technical breakthroughs in maize resilience biotechnology still face barriers including genotype-dependent transformation efficiency, regulatory landscapes, and implementation costs in resource-limited settings.
Quoted textsource-backed
Despite these technical breakthroughs, barriers such as genotype-dependent transformation efficiency, regulatory landscapes, and implementation costs in resource-limited settings remain.
Integrating molecular breakthroughs with practical deployment strategies offers a roadmap for developing sustainable, climate-resilient maize varieties.
Quoted textsource-backed
By integrating molecular breakthroughs with practical deployment strategies, this review offers a comprehensive roadmap for developing sustainable, climate-resilient maize varieties to meet future agricultural demands.
The review presents an integrated framework for enhancing maize resilience under climate change that includes CRISPR/Cas9, next-generation genome editing, genomic selection, environmental genomic selection, and multi-omics platforms.
Quoted textsource-backed
We present an integrated framework that encompasses CRISPR/Cas9 and next-generation genome editing, Genomic Selection (GS), Environmental Genomic Selection (EGS), and multi-omics platforms-spanning transcriptomics, proteomics, metabolomics, and epigenomics.
This editorial summarizes a Research Topic on genome editing for climate-change adaptation in agriculture, emphasizing innovations, applications, and regulatory considerations.
The source states that major challenges for engineered anti-herbivore traits include limited field validation, ecological trade-offs, and regulatory hurdles.
CRISPR/Cas9-mediated genome editing can amplify risk through off-target double-strand breaks and chromosomal rearrangements.
Quoted textsource-backed
CRISPR/Cas9-mediated genome editing further amplifies risks via off-target double-strand breaks and chromosomal rearrangements.
Genetic engineering technologies including CRISPR-Cas9 create new opportunities for emerging cellular therapies and for improving CAR-modified T cells.
Quoted textsource-backed
Propelled by viral and non-viral-based technologies, such as CRISPR-Cas9, genetic engineering offers novel opportunities for both emerging cellular therapies and the improvement of more established approaches such as chimeric antigen receptor (CAR) modified T cells.
The source states that CRISPR/Cas9, RNA interference, and metabolic engineering are cutting-edge technologies reshaping pest management.
The editorial explicitly highlights guide RNA design, in planta transformation, CRISPR/Cas9-based climate resilience, and regulation as major themes in agricultural genome editing.
The hairy-root-based evaluation system was validated using CRISPR/Cas9, supporting its effectiveness.
Quoted textsource-backed
We first validated the system using the CRISPR/Cas9 genome editing platform, confirming its effectiveness.
Vector choice and engineering methods are important considerations in optogenetics and targeted gene therapies for inherited retinal diseases.
Quoted textsource-backed
The importance of vector choice and engineering methods are discussed.
Engineering and cell or tissue delivery capabilities are limiting challenges for prompt clinical introduction of optogenetics and targeted gene therapy.
Quoted textsource-backed
the challenges limiting their prompt introduction into the clinical practice (i.e., engineering, cell or tissue delivery capabilities)
Targeted gene therapies based on CRISPR-Cas9 and RNA interference are described as inducing normal gene or protein expression into affected cells.
Quoted textsource-backed
targeted gene therapies, such as methods based on CRISPR-Cas9 and RNA interference with noncoding RNAs (i.e., microRNA, small interfering RNA, short hairpin RNA), consists of inducing normal gene or protein expression into affected cells.
Optogenetics and targeted gene therapies are presented as having clinical potential for inherited retinal diseases and personalized medicine.
Quoted textsource-backed
optogenetics and targeted gene therapies have shown great clinical potential and novelty in the branch of personalized medicine and inherited retinal diseases (IRDs).